Question 1

What are the potential benefits of participating in this trial compared to my current treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor clinical trial (NCT06556862). Contact the study team or your healthcare provider for specific answers.

Question 2

What side effects should I expect from dalpiciclib and the other medications?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor clinical trial (NCT06556862). Contact the study team or your healthcare provider for specific answers.

Question 3

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor clinical trial (NCT06556862). Contact the study team or your healthcare provider for specific answers.

Question 4

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor clinical trial (NCT06556862). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any travel or logistical considerations I should be aware of for participating?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor clinical trial (NCT06556862). Contact the study team or your healthcare provider for specific answers.

Question 6

How long will I need to participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor clinical trial (NCT06556862). Contact the study team or your healthcare provider for specific answers.

What this study is about